A Meta-Analysis of Resveratrol Protects against Myocardial Ischemia/Reperfusion Injury: Evidence from Small Animal Studies and Insight into Molecular Mechanisms
Table 7
Metaregression analysis in vivo and ex vivo.
Covariates
Infarct size (in vivo studies)
Infarct size (ex vivo studies)
Coefficient
95% CI
value
Coefficient
95% CI
value
Species
6.122819
-6.043731; 18.28937
0.279
5.763822
-8.045439; 19.57308
0.332
Sample size
1.662638
-1.379227; 4.704503
0.243
0.2914345
-0.869869; 1.452738
0.547
State
1.953709
-11.39187; 15.29928
0.744
-0.774244
-6.697155; 5.148667
0.750
Route of administration
4.398078
-12.15415; 20.9503
0.557
4.566912
-4.397479; 13.5313
0.247
Reperfusion duration
-9.196691
-29.21135; 10.81797
0.320
1.047275
-5.011723; 7.106273
0.675
Timing regimen of pretreatment
2.226924
-3.267802; 7.721649
0.377
0.7420125
-1.891014; 3.375039
0.501
Metaregression provided valuable information regarding the interaction between the continuous covariates and treatment effect of resveratrol in reducing the infarct size and may explore the source of heterogeneity. Consistent value showed that none of the covariates below had an impact on the cardioprotection of resveratrol in myocardial I/R injury.
